DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kang, Byeong Hoon | ko |
dc.contributor.author | Lee, Heung Kyu | ko |
dc.date.accessioned | 2022-07-19T05:00:52Z | - |
dc.date.available | 2022-07-19T05:00:52Z | - |
dc.date.created | 2022-07-19 | - |
dc.date.created | 2022-07-19 | - |
dc.date.created | 2022-07-19 | - |
dc.date.issued | 2022-07 | - |
dc.identifier.citation | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, v.23, no.13 | - |
dc.identifier.issn | 1661-6596 | - |
dc.identifier.uri | http://hdl.handle.net/10203/297391 | - |
dc.description.abstract | Dendritic cells mediate innate and adaptive immune responses and are directly involved in the activation of cytotoxic T lymphocytes that kill tumor cells. Dendritic cell-based cancer immunotherapy has clinical benefits. Dendritic cell subsets are diverse, and tumors can be hot or cold, depending on their immunogenicity; this heterogeneity affects the success of dendritic cell-based immunotherapy. Here, we review the ontogeny of dendritic cells and dendritic cell subsets. We also review the characteristics of hot and cold tumors and briefly introduce therapeutic trials related to hot and cold tumors. Lastly, we discuss dendritic cell-based cancer immunotherapy in hot and cold tumors. | - |
dc.language | English | - |
dc.publisher | MDPI | - |
dc.title | Dendritic Cell-Based Immunotherapy in Hot and Cold Tumors | - |
dc.type | Article | - |
dc.identifier.wosid | 000822214100001 | - |
dc.identifier.scopusid | 2-s2.0-85133667235 | - |
dc.type.rims | ART | - |
dc.citation.volume | 23 | - |
dc.citation.issue | 13 | - |
dc.citation.publicationname | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | - |
dc.identifier.doi | 10.3390/ijms23137325 | - |
dc.contributor.localauthor | Lee, Heung Kyu | - |
dc.description.isOpenAccess | N | - |
dc.type.journalArticle | Review | - |
dc.subject.keywordAuthor | dendritic cells | - |
dc.subject.keywordAuthor | hot tumor | - |
dc.subject.keywordAuthor | cold tumor | - |
dc.subject.keywordAuthor | dendritic cell-based immunotherapy | - |
dc.subject.keywordPlus | MEDIATED ANTITUMOR IMMUNITY | - |
dc.subject.keywordPlus | CYTOTOXIC T-CELLS | - |
dc.subject.keywordPlus | I CLINICAL-TRIAL | - |
dc.subject.keywordPlus | CANCER-IMMUNOTHERAPY | - |
dc.subject.keywordPlus | TRANSCRIPTION FACTOR | - |
dc.subject.keywordPlus | STEADY-STATE | - |
dc.subject.keywordPlus | REGULATORY FACTOR-4 | - |
dc.subject.keywordPlus | SIGNALING CONTROLS | - |
dc.subject.keywordPlus | CROSS-PRESENTATION | - |
dc.subject.keywordPlus | NY-ESO-1 PROTEIN | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.